Inotec AMD secures £7m Series A funding led by Praetura Capital to expand internationally.
The investment round was led by Praetura Capital with backing from Boundary Capital Partners and other investors.
Inotec AMD develops medical technology for wound therapy, offering a device that generates pure humidified oxygen to treat complex chronic wounds. The business supplies healthcare providers and the NHS across multiple international markets.
Inotec AMD has raised £7m in a Series A funding round led by Praetura Capital. The investment also drew participation from Boundary Capital Partners, Amadeus Capital Partners, Puhua Capital, and a group of angel investors.
The company has created a medical device named NATROX Oxygen, which produces pure humidified oxygen to assist with the treatment of various chronic wounds, including diabetic and venous ulcers. Following positive clinical trials, the business intends to use the capital to expand its presence across international markets such as the US, Asia, the Middle East, and Europe.
From the founder
"The UK alone spends £3.1bn on treating chronic wounds each year, while the US spends $50bn. Add to this the significant escalation in costs, not to mention the considerable distress to patients and families if the only course of treatment for non-healing wounds is amputation. It’s clear that there’s a real need for innovation in this area."
Craig Kennedy
CEO at Inotec AMD
Investor perspective
"Our mantra is to back dynamic businesses led by highly-skilled, respected and entrepreneurial management teams."
Dan Somers
Managing Partner, Boundary Capital Partners
Use of funds
- 01Expand into international markets
Investors
Categories
About the company
Inotec AMD
Inotec AMD develops medical technology designed to heal complex chronic wounds.